### Supplemental Table S1. Clinical Characteristics of Patients in No Overt Hypothyroidism Group According to the Recovery of Thyroid Dysfunction (n=139)

| Characteristic                        | Recovery (n=84) | No recovery (n=55) | P value |
|---------------------------------------|----------------|--------------------|---------|
| Age, yr                               | 65.9±11.4      | 66.0±11.3          | 0.940   |
| Female sex                            | 22 (26.2)      | 18 (32.7)          | 0.405   |
| PD-1/PD-L1 inhibitor                  |                |                    | 0.298   |
| Pembrolizumab                         | 36 (42.9)      | 22 (40.0)          |         |
| Nivolumab                             | 33 (39.3)      | 19 (34.5)          |         |
| Durvalumab                            | 4 (4.8)        | 2 (3.6)            |         |
| Atezolizumab                          | 11 (13.1)      | 12 (21.8)          |         |
| Duration of PD-1/PD-L1 inhibitor therapy, mo | 6.0 (2.0–12.0) | 2.0 (1.0–5.0)      | <0.001  |
| No. of doses of PD-1/PD-L1 inhibitor | 9.0 (4.0–17.0) | 5.0 (3.0–9.0)      | 0.001   |
| Baseline TSH level                    | 2.23±1.37      | 2.62±1.54          | 0.138   |
| Baseline free T4 level                | 1.24±0.18      | 1.22±0.18          | 0.626   |
| The last thyroid function status      |                |                    | <0.001  |
| Normal                                | 84 (100.0)     | 0                  |         |
| Subclinical hypothyroidism            | -              | 42 (76.4)          |         |
| Subclinical hyperthyroidism           | -              | 6 (10.9)           |         |
| Overt hyperthyroidism                 | -              | 7 (12.7)           |         |

Values are expressed as mean ± standard deviation, number (%), or median (interquartile range). PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1; TSH, thyroid stimulating hormone; T4, thyroxine. *All patients (n=7) were negative for TSH binding inhibitory immunoglobulin.